WINNIPEG, Aug. 8, 2018 /CNW/ - Medicure Inc. ("Medicure")
(TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2018 on Wednesday, August 15, 2018. The second quarter financial
statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, August 16, 2018 at 7:30 AM Central Time (8:30 AM
Eastern Time).
Conference Call Info:
Topic: Medicure's Q2 2018 Results
Call date: Thursday August 16, 2018
Time: 7:30 AM Central Time (8:30 AM Eastern Time)
Canada toll-free: 1 (888) 465-5079 Canada
toll: 1 (416) 216-4169
United States toll-free: 1 (888) 545-0687
Passcode: 5781086#
Webcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations
page at the following link: http://www.medicure.com/investors.html
You may request international country-specific access information by e-mailing the Company in advance. Management will accept
and answer questions related to the financial results and operations during the question-and-answer period at the end of the
conference call. A recording of the call will be available following the event at the Company's website.
About Medicure
Medicure is a pharmaceutical company focused on the development and commercialization of therapeutics for the U.S.
cardiovascular market. The primary focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban
hydrochloride) injection and ZYPITAMAGTM (pitavastatin) tablets in the United States,
where they are sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit
www.medicure.com.
To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Medicure Inc.
View original content: http://www.newswire.ca/en/releases/archive/August2018/08/c1529.html